<SEC-DOCUMENT>0001372514-23-000101.txt : 20230615
<SEC-HEADER>0001372514-23-000101.hdr.sgml : 20230615
<ACCEPTANCE-DATETIME>20230615165900
ACCESSION NUMBER:		0001372514-23-000101
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230612
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230615
DATE AS OF CHANGE:		20230615

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KIORA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001372514
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36672
		FILM NUMBER:		231018199

	BUSINESS ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024
		BUSINESS PHONE:		781-788-8869

	MAIL ADDRESS:	
		STREET 1:		332 ENCINITAS BOULEVARD
		STREET 2:		SUITE 102
		CITY:			ENCINITAS
		STATE:			CA
		ZIP:			92024

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EYEGATE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060811
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>kprx-20230612.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:3fc74ccf-9297-43b4-8bd6-d0324616345f,g:2a091e00-480d-4af7-9ce8-bab735938b6e,d:50f9c321473f42f699ab6ffb81ffd1a8--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>kprx-20230612</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8yLTEtMS0xLTQyNjE4_7b264685-00de-4646-a1df-923c26d6f57a">0001372514</ix:nonNumeric><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8zLTEtMS0xLTQyNjE4_7d56551b-53f4-492d-a437-f9a508398aa2">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="kprx-20230612.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001372514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-12</xbrli:startDate><xbrli:endDate>2023-06-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:8pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzAy_2bff1795-c87e-4f86-bbcb-c11654d6491c">8-K</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">CURRENT REPORT PURSUANT</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">TO SECTION 13 OR 15(d) OF THE</span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported): </span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8yMjM_be48fbeb-c8ea-4c38-b45e-e6fdd44b8702">June 12, 2023</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA2_2dd9dadd-e5aa-48da-a73b-11abc7b7f979">KIORA PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEy_b1d77c16-852d-4f08-b11a-c3a30845949e">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTAtMS0xLTQyNjE4_e7ce04dd-1eb2-4154-8069-abbbefa40d30">001-36672</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTEtMS0xLTQyNjE4_bf1d6144-4b1a-4c4e-b5aa-b5915a26affc">98-0443284</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA0_5ee33721-e45c-4ec6-80d3-395bd099bc34">332 Encinitas Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEw_4c5543f0-af57-491f-a1b8-4f1ba5a2e993">Suite 102</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE1_b8bde44d-1966-496a-bb0a-af429d61caba">Encinitas</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA5_d5605d37-18e3-4783-bd6c-0f570906d767">CA</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTQ_91c418b4-3997-45d6-8985-e661891ca6c8">92024</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTg_54acb35f-46f3-4dbc-9aeb-d5e555f5a093">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA1_7384835e-f3ab-46a9-863a-15f0599c0407">224-9600</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8wLTAtMS0xLTQyNjE4_8dbffde0-b9ff-40fc-a2b5-eaf16deeb473">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8yLTAtMS0xLTQyNjE4_3f1eb3a8-f9bb-4d0f-9005-e49663e06f39">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl80LTAtMS0xLTQyNjE4_71300be7-f4cf-4452-949d-597e4d487e38">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl82LTAtMS0xLTQyNjE4_38d1facc-cc25-48a7-99e2-3b537510de13">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered:</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTAtMS0xLTQyNjE4_761545d6-2971-45eb-a8df-f19c596fe894">Common Stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTItMS0xLTQyNjE4_07eac58d-657c-4d9d-967f-fd27060c73f0">KPRX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTQtMS0xLTQyNjE4_decc6269-0e76-49cc-885d-e4ebf2cda371">NASDAQ</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE2_5f3bf06b-3061-4b61-985f-a57b794662e4">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMjk5_5f3bf06b-3061-4b61-985f-a57b794662e4">&#9744;</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 1.01.&#160;&#160;&#160;&#160;Entry into a Material Definitive Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As previously reported, on September 26, 2018, Kiora Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an Intellectual Property License Agreement (the &#8220;2018 Agreement&#8221;) with Sentrx Animal Care, Inc. (&#8220;Sentrx&#8221;), with respect to certain rights relating to the manufacturing of the Company&#8217;s KIO-201 product candidate.  Under the 2018 Agreement, Sentrx granted to the Company an exclusive license to use Sentrx&#8217;s procedures, trade secrets, know-how and other relevant intellectual property in connection with the production of KIO-201.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the 2018 Agreement, the Company paid Sentrx an upfront payment of $250,000 and agreed to pay Sentrx milestone payments totaling up to $4.75 million (the &#8220;Milestone Payments&#8221;), upon and subject to the achievement of certain specified developmental and commercial milestones. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 12, 2023 and effective as of June 7, 2023 (the &#8220;Effective Date&#8221;), the Company and Sentrx entered into a First Amendment to the 2018 Agreement (the &#8220;Amendment&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the Amendment, among other things, the Company is no longer obligated to pay any of the Milestone Payments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also on June 12, 2023 and effective as of the Effective Date, the Company and Sentrx entered into an Exclusive License Agreement (the &#8220;2023 Agreement&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the 2023 Agreement, the Company granted to Sentrx an exclusive and sublicensable license to certain patents related to KIO-201 in the field of animal health for diseases or conditions of the eye and its adnexa, and Sentrx is obligated to pay to the Company a low single-digit royalty on net sales of products covered by the licensed patents. The license granted by the 2023 Agreement will remain in effect for the duration of the licensed patents unless earlier terminated in accordance with its terms.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing descriptions of the Amendment and the 2023 Agreement do not purport to be complete descriptions of all of the terms of the Amendment and the 2023 Agreement, and are qualified in their entirety by reference to the full text of the Amendment and the 2023 Agreement, copies of which are filed as Exhibit 10.1 and Exhibit 10.2 hereto, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_13"></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01 Other Events.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 15, 2023, the Company issued a press release announcing the Amendment and the 2023 Agreement, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_16"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits</span></div><div style="margin-top:10pt;padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:0.74pt"> Exhibits.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit101.htm">First Amendment to Intellectual Property License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit102.htm">Exclusive License Agreement, dated as of June 12, 2023, between Kiora Pharmaceuticals, Inc. and Sentrx Animal Care, Inc.</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-pressreleasejun.htm">Press Release of Kiora Pharmaceuticals, Inc., dated as of June 15, 2023</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8224; Certain confidential portions of this exhibit were omitted pursuant to Item 601(b)(2)(ii) of Regulation S-K because the identified confidential portions (i) are not material and (ii) are customarily and actually treated as private or confidential by the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i50f9c321473f42f699ab6ffb81ffd1a8_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#212529;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.841%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">KIORA PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal executive officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: June 15, 2023</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie57b2b66e69d4a1e86c11ec13614e988_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY &#91;***&#93;.</font></div><div style="margin-top:0.45pt;text-align:center"><font><br></font></div><div style="margin-top:0.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%;text-decoration:underline">FIRST AMENDMENT</font></div><div style="margin-top:12.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">This First Amendment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:128%">(&#34;First Amendment&#34;) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">to the Intellectual Property License Agreement dated September 26, 2018 (the &#34;Agreement&#34;) is effective as of June 7, 2023 (the &#34;Effective Date&#34;), by and between the Kiora Pharmaceuticals, Inc., a Delaware corporation with an address at 332 Encinitas Blvd, Suite 102, Encinitas, CA 92024 (formerly located at&#58; 271 Waverley Oaks Road, Suite 108, Waltham, MA 02452) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:128%">(&#34;Kiora&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">and Sentrx Animal Care, Inc. a Delaware corporation with an address at 570 West 1700 South, Suite 1400, Salt Lake City, Utah 84115 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:128%">(&#34;Sentrx&#34;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:128%">each a &#34;Party&#34; and collectively, the &#34;Parties&#34;).</font></div><div style="margin-top:7.1pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">RECITALS</font></div><div style="margin-top:6.35pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, Kiora's predecessor EyeGate Pharmaceuticals, Inc. and Sentrx previously entered into the &#34;Agreement and now desire to amend certain terms to the Agreement&#59;</font></div><div style="margin-top:12.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, Sentrx has been making, using, offering for sale, and selling eye and wound care products in the fields of veterinary medicine, animal health, and cosmetic uses pursuant to Sentrx's exclusive license agreement with the University of Utah Research Foundation (the &#34;U of U License&#34;)&#59;</font></div><div style="margin-top:12.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, Kiora is a clinical-stage specialty pharmaceutical company developing and commercializing therapies for the treatment of ophthalmic diseases in humans including, for example, KIO-201&#59;</font></div><div style="margin-top:12.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, the Agreement was entered into by the Parties so that Sentrx could assist Kiora in the manufacturing and production of the Product in accordance with Kiora's Licensed Use, which Product includes KIO-201&#59;</font></div><div style="margin-top:13.2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">WHEREAS, Sentrx has been making, selling, and providing the Product to Kiora&#59;</font></div><div style="margin-top:13.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, the Parties desire that Kiora has no obligation to make any further payments to Sentrx (Milestone or otherwise) that were set forth the Agreement&#59;</font></div><div style="margin-top:12.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, the Parties desire that Sentrx has no obligation to provide any further services or support to Kiora that were set forth in the Agreement&#59;</font></div><div style="margin-top:12.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">WHEREAS, the Parties desire that Kiora can continue to use the information, know-how, and Technology previously provided by Sentrx for use in and on the human eye and its adnexa (&#34;Field of Use&#34;)&#59;</font></div><div style="margin-top:12.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">WHEREAS, the Parties desire that Sentrx has no obligation to provide any further information, know-how, or Technology to Kiora related to production of the Product&#59; and</font></div><div style="margin-top:13.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">WHEREAS, the Parties desire that this First Amendment or the Agreement do not preclude the Parties from entering into a future agreement or business relationship in which Sentrx provides any of products, services, and&#47;or support to Kiora&#59;</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">NOW THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, as well as agreement by the Parties to enter into a second</font></div><div style="margin-top:0.55pt;padding-left:3.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:114%">Intellectual Property License Agreement substantially simultaneously herewith, the Parties hereby enter into this First Amendment and agree as follows&#58;</font></div><div style="margin-top:13.05pt;padding-left:1.8pt;padding-right:1.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:114%">AMENDMENT</font></div><div style="margin-top:19.9pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Notwithstanding anything to the contrary in the Agreement, &#34;Licensed Use&#34; means to use, commercialize, and exploit the Technology solely for the production of the Product only in the Field of Use, which does not include, for the avoidance of doubt, any rights granted to Licensor pursuant to the &#91;***&#93;.</font></div><div style="margin-top:13.95pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Notwithstanding anything to the contrary in the Agreement, &#34;Field of Use&#34; means the human eye and its adnexa.</font></div><div style="margin-top:13.9pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Sections 2(a)ii &#8212; 2(a)vi of the Agreement are deleted in their entirety along with any Party obligations set forth therein.</font></div><div style="margin-top:13.9pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Section 2(c) of the Agreement is deleted in its entirety along with any Party obligations set forth therein.</font></div><div style="margin-top:13.9pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Section 2(d) of the Agreement is deleted in its entirety along with any Party obligations set forth therein.</font></div><div style="margin-top:13.9pt;padding-left:36pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Section 3(e) of the Agreement is deleted in its entirety along with any Party obligations set forth therein.</font></div><div style="margin-top:6.9pt;padding-left:50.4pt;padding-right:28.8pt;text-align:justify;text-indent:-46.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;padding-left:38.18pt">Section 5 of the Agreement is deleted and replaced with the following language&#58;</font></div><div style="margin-top:6.9pt;padding-left:50.4pt;padding-right:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:186%">5. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:186%;text-decoration:underline">Manufacturing&#59; Research and Developments </font></div><div style="margin-top:7.3pt;padding-left:50.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">Licensee may outsource any manufacturing or other research or development and any related support or services for the Product that incorporates the Technology in accordance with the Licensed Use.</font></div><div style="margin-top:7.3pt;padding-left:36pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Section 8 of the Agreement is deleted and replaced with the following language&#58;</font></div><div style="margin-top:7.35pt;padding-left:50.4pt;padding-right:28.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:123%">8. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:123%;text-decoration:underline">Term and Renewal.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%"> This Agreement shall commence on the Effective Date and shall continue until the date that the Product is no longer in the commercial marketplace (the &#34;Term&#34;).</font></div><div style="margin-top:7.6pt;padding-left:36pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:23.78pt">Section 10 of the Agreement is amended to include the following&#58;</font></div><div style="margin-top:13.6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">Licensor has no obligation to provide any further information, know-how, or Technology to Kiora, and Kiora confirms and agrees that Licensor has fully complied with any past obligations to provide information, know-how, or Technology to Kiora.</font></div><div style="margin-top:13.9pt;padding-left:36pt;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;padding-left:18.03pt">Section 11(b) of the Agreement is deleted and replaced with the following language&#58;</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:7.4pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">(b) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%;text-decoration:underline">Indemnification by Licensor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%"> Licensor shall indemnify, defend and hold <br>harmless Licensee, its officers, directors, members, managers, employees, agents, and representatives from and against any and Claims to the extent arising out of or resulting from (i) any representation or warranty by Licensee set forth herein being untrue in any material respect when made or any material breach or material default by Licensee of any of its covenants or other obligations hereunder&#59; (ii) any claim, demand, suit, proceeding, investigation, or other action of any nature related to any Licensor intellectual property&#59; or (iii) any claim, demand, suit, proceeding, investigation, or other action of any nature relating to or arising out of Licensor's action or inaction prior to or after the Effective Date.</font></div><div style="margin-top:7.6pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">11.&#160;&#160;&#160;&#160;Section 13(b) of the Agreement is deleted and replaced with the following text&#58;</font></div><div style="margin-top:9.05pt;padding-left:54pt;padding-right:32.4pt;text-align:justify;text-indent:-14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:1.66pt;text-decoration:underline">Effect of Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%"> Upon any expiration or termination of this Agreement for any reason whatsoever, all rights in and to the Technology shall revert to Licensor and, except in the event of an uncured default by Licensor, Licensee shall have no further rights whatsoever with respect to the Technology and&#47;or any other intellectual property rights relating thereto. In such event other than an uncured default by Licensor, Licensee shall, at its sole cost and expense, return any of Licensor's intellectual property of any kind that are then in its possession or under its control. In the event of an uncured default by Licensor, at the sole option of Licensee, the License will continue in effect and Licensee will continue to have all the rights and obligations, including any payment obligations, set forth in this Agreement. In no event shall any expiration or termination of this Agreement excuse any Party from any breach or violation of this Agreement and full legal and equitable remedies shall remain available therefor, nor shall it excuse the making of any payment due under this Agreement with respect to any period prior to the date of expiration or termination. Notwithstanding any provision of this Agreement to the contrary, Sections 3, 4, 6, 8, and 9 &#8212; 18 hereof shall survive any expiration or termination of this Agreement.</font></div><div style="margin-top:7.6pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">12.&#160;&#160;&#160;&#160;Section 17 of the Agreement is deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:12.3pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;text-decoration:underline">Sublicensing, Assignment, and Transfer.</font></div><div style="margin-top:12.9pt;padding-left:54pt;padding-right:14.4pt;text-align:justify;text-indent:-14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;padding-left:1.66pt;text-decoration:underline">Assignment and Transfer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%"> Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without providing &#91;***&#93; prior written notice to the other Party. For the avoidance of doubt, each Party may make such an assignment or transfer without the other Party's consent to such Party's Affiliate or to the successor to all or substantially all of the business of such Party to which this Agreement relates (whether by merger, change of control, acquisition or sale of assets)&#59; provided that each Party must give prompt written notice to the other Party in the event of such a transaction.</font></div><div style="margin-top:12.25pt;padding-left:54pt;text-align:justify;text-indent:-14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:1.01pt;text-decoration:underline">Sublicensing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%"> </font></div><div style="margin-top:12.5pt;padding-left:39.6pt;padding-right:14.4pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">i.&#160;&#160;&#160;&#160;The license granted in Section 1 of this Agreement includes the right of Licensee to sublicense all or any of its licensed rights to and under the </font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.5pt;padding-left:39.6pt;padding-right:14.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">Licensed Patents to a Sublicensee provided that such Sublicensee shall assume the same obligations and the same terms and conditions as Licensee hereunder&#59; and further provided that Licensee shall be responsible for the performance of all of such obligations, and for compliance with all of such terms and conditions, by Sublicensee. Licensee shall remain liable for the performance of all Licensee obligations under this Agreement and for the actions or inactions of any and all Sublicensees as if such actions or inactions were carried out by the Licensee itself.</font></div><div style="margin-top:12.75pt;padding-left:32.4pt;padding-right:21.6pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">ii.&#160;&#160;&#160;&#160;No sublicense may exceed the scope of rights granted to Licensee hereunder. Licensee shall require all sublicenses to be in writing and to include an agreement by the Sublicensee to be bound by the terms and conditions of this Agreement. Each sublicense granted hereunder shall be consistent with and comply with all terms of this Agreement, shall incorporate terms and conditions sufficient to enable Licensee to comply with this Agreement, and shall provide that Licensor is a third party beneficiary thereof (solely for purposes of enforcing its rights to any provisions which are for the benefit of Licensor and Indemnitees therein). Licensee shall provide to Licensor a fully executed copy of all sublicense agreements and amendments thereto, including all exhibits, attachments and related documents, within &#91;***&#93; of executing the same, provided that Licensee may redact such copy provided to Licensor to remove financial or other sensitive business terms. Upon termination or expiration of this Agreement for any reason, any sublicenses shall terminate effective as of the termination or expiration of this Agreement. Any sublicense that is not in accordance with the foregoing provisions shall be null and void.</font></div><div style="margin-top:11.3pt;padding-left:32.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:124%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:124%;padding-left:14.43pt">Section 18(c) of the Agreement is deleted in its entirety along with any Party obligations set forth therein.</font></div><div style="margin-top:14.7pt;padding-left:32.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;padding-left:14.43pt">Annex I of the Agreement is deleted in its entirety and is replaced with the following&#58;</font></div><div style="margin-top:15.4pt;padding-left:50.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;padding-left:14.18pt">The &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">&#34; is further defined as &#91;***&#93;.</font></div><div style="margin-top:14.35pt;padding-left:50.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;padding-left:14.18pt">The &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;text-decoration:underline">Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">&#34; is further defined as &#91;***&#93;.</font></div><div style="margin-top:14.1pt;padding-left:50.4pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%">&#183;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:113%;padding-left:14.18pt">Licensor shall waive the restrictive covenants binding &#91;***&#93;, pursuant to all written agreements entered into between &#91;***&#93; and Licensor, to permit &#91;***&#93; to assist Licensee with its use of the Technology and its production of the Product.</font></div><div style="margin-bottom:25pt;margin-top:19.8pt;padding-left:32.4pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:123%">15.&#160;&#160;&#160;&#160;Definitions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:123%">Capitalized terms used but not otherwise defined in this First Amendment shall have the meanings ascribed to such capitalized terms in the Agreement.</font></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:125%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:125%;padding-left:12.63pt">&#160;&#160;&#160;&#160;Ratification of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:125%">. Except as provided herein or as may be required to &#160;&#160;&#160;&#160;effectuate the intent of the Parties with respect to the amendments described herein, the Parties hereby reaffirm and ratify the terms of the Agreement in their entirety.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:125%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:125%;padding-left:21.63pt">Entire Understanding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:125%">. This First Amendment, including the Recitals incorporated herein by this reference, constitutes the entire understanding between the Parties hereto with respect to the subject matter hereof and any modifications of the Agreement resulting therefrom.  Any further modifications to the Agreement shall be in writing and shall be signed by a duly authorized representative of each Party.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.375%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, this First Amendment has been executed by duly authorized representatives of the Parties on the date stated below.</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">KIORA PHARMACEUTICALS, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SENTRX ANIMAL CARE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Brian M. Strem, Ph.D.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By &#47;s&#47; Brian Segebrecht</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brian M. Strem, Ph.D., President &#38; CEO</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date 12 June 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Brian Segebrecht, President &#38; CEO</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date June 7, 2023</font></div></td></tr></table></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i53841b04ae5e4d2ea079a1f72f29ab57_1"></div><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:130%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL TO THE REGISTRANT AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS SUCH INFORMATION AS PRIVATE OR CONFIDENTIAL. REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY &#91;***&#93;.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:116%">EXCLUSIVE LICENSE AGREEMENT</font></div><div style="margin-top:11.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">This Exclusive License Agreement (&#34;Agreement&#34;), dated June 7, 2023 (&#34;Effective Date&#34;), is by and between Kiora Pharmaceuticals, Inc., a Delaware corporation with offices located at 332 Encinitas Blvd, Suite 102, Encinitas, CA 92024 (&#34;Licensor&#34;), and Sentrx Animal Care, Inc. a Delaware corporation with offices located at 570 West 1700 South, Suite 1400, Salt Lake City, Utah 84115 (&#34;Licensee&#34;) (collectively, the &#34;Parties,&#34; or each, individually, a &#34;Party&#34;).</font></div><div style="margin-top:14.25pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:116%">WHEREAS, Licensor owns the Licensed Patents (defined below)&#59;</font></div><div style="margin-top:13.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">WHEREAS, Licensor has the right, power, and authority to license to Licensee the Licensed Patents&#59;</font></div><div style="margin-top:13.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">WHEREAS, Licensor is willing to grant to Licensee an exclusive license to the Licensed Patents on the terms and conditions set out in this Agreement&#59; and</font></div><div style="margin-top:13.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">WHEREAS, this Agreement is intended to provide Licensee with exclusive rights to the Licensed Patents, and to make, have made, use, and sell products using the Licensed Patents, in connection with animal health and veterinary medicine.</font></div><div style="margin-top:13.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the mutual covenants, terms, and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows&#58;</font></div><div style="margin-top:12.6pt;padding-left:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:119%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:119%;text-decoration:underline">Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:119%"> For purposes of this Agreement, the following terms have the following</font></div><div style="margin-top:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:116%">meanings&#58;</font></div><div style="margin-top:12.15pt;padding-left:21.6pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Affiliate&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">means an entity that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such entity. The term &#34;control&#34; for purposes of this Agreement means the power to direct or cause the direction of the management and policies of an entity, whether through the ownership, by contract, or otherwise, and &#34;controlled by&#34; and &#34;under common control with&#34; have correlative meanings.</font></div><div style="margin-top:13.9pt;padding-left:21.6pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Bankruptcy Code&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">means the United States Bankruptcy Code, as amended from time to time, any successor statute or rule promulgated in furtherance thereof.</font></div><div style="margin-top:13.9pt;padding-left:21.6pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Field of Use&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">means the treatment, amelioration, mitigation, or prevention of diseases or conditions of the eye and its adnexa in any and all dosage forms and modes of administration for veterinary medical use and animal health.</font></div><div style="margin-top:13.7pt;padding-left:21.6pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:121%">&#34;Improvement&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">means any modification of or improvement or enhancement to the technology disclosed in the Licensed Patents.</font></div><div style="margin-top:13.85pt;padding-left:21.6pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:120%">&#34;Licensed Patents&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">means (a) the patents and patent applications listed in Schedule A and (b) patent applications claiming priority thereto and any patents that issue </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.85pt;padding-left:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">therefrom, as well as any continuation, continuation-in-part, divisional, extension, substitution, reissue, re-examination, and renewal of any of the foregoing.</font></div><div style="padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font><br></font></div><div style="padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#34;Licensed Products&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means any products covered by a Valid Claim of any of the Licensed Patents.</font></div><div style="margin-top:13.95pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#34;Losses&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means all losses, damages, liabilities, deficiencies, claims, actions, judgments, settlements, interest, awards, penalties, fines, costs, or expenses of whatever kind, including reasonable attorneys' fees and the cost of enforcing any right to indemnification hereunder, and the cost of pursuing any insurance providers.</font></div><div style="margin-top:14.35pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#34;Net Sales&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">means the gross sales of Licensed Products by Licensee, including of its Affiliates and Sublicensees, to any third party less the sum of the following deductions and offsets that are actually incurred, allowed, accrued, paid, or taken and are allocated with respect to such sale or distribution, but solely to the extent that such deductions or offsets are not otherwise recovered by or reimbursed to Licensee or the applicable Affiliate or Sublicensee&#58; (a) &#91;***&#93;&#59; (b) &#91;***&#93;&#59; (c) &#91;***&#93;&#59; (d) &#91;***&#93;. Licensed Products will be considered &#34;sold&#34; at the earlier of&#58; (y) &#91;***&#93;&#59; or (z) &#91;***&#93;.</font></div><div style="margin-top:13.9pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">For purposes of clarity, no deductions are permitted for purposes of calculating Net Sales on the following items&#58; &#91;***&#93;&#59; and &#91;***&#93;.</font></div><div style="margin-top:14.3pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#91;***&#93; will be deemed a transfer for the purpose of determining Net Sales. Net Sales on all Licensed Product &#91;***&#93; will be calculated at &#91;***&#93;. In the event Licensee transfers Licensed Product to an Affiliate, and the Affiliate re-transfers the Licensed Product to third party customers, then the Net Sales will be &#91;***&#93;. In the event a Licensed Product is sold in combination with another product or other products, wherein the combination product does not itself constitute a Licensed Product, then Net Sales, for purposes of calculating royalty payments on the combination product(s), will be calculated by &#91;***&#93;. If Licensee does not sell the Licensed Product separate from a combination product, then Net Sales, for purposes of calculating royalty payments on the combination product will exclude the &#34;Value&#34; (as defined below) of any non-Licensed</font></div><div style="padding-left:10.8pt;padding-right:10.8pt;text-align:justify"><font><br></font></div><div style="padding-left:10.8pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Product included in the combination product. In this circumstance, &#34;Value,&#34; for purposes of this &#34;combination product&#34; provision, means &#91;***&#93;. The calculation of Net Sales of combination products will be subject to the Licensor's audit rights set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Section 6 herein.</font></div><div style="margin-top:13.25pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">A Sublicensee does not include any person or entity purchasing Licensed Products from Licensee, its Affiliate or its Sublicensee under a distributorship arrangement.</font></div><div style="margin-top:13.8pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">All calculations of Net Sales must be in accordance with generally accepted accounting principles (&#34;GAAP&#34;) and based on, or valued as if based on, bona fide arms' length transactions and not on any &#91;***&#93;.</font></div><div style="margin-top:13.75pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:116%">&#34;Person(s)&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">means an individual, corporation, partnership, joint venture, limited liability company, governmental authority, unincorporated organization, trust, association, or other entity.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.55pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:116%">&#34;Quarterly Period&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">means each period of three (3) consecutive months ending on March 31, June 30, September 30, and December 31.</font></div><div style="margin-top:13.2pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">&#34;Representatives&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">means a Party's employees, officers, directors, and legal advisors.</font></div><div style="margin-top:13.4pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:116%">&#34;Sublicensee&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">means any Person or entity that is granted a sublicense, in whole or in part, by Licensee under this Agreement.</font></div><div style="margin-top:13.55pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:64.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:116%">&#34;Subsidiary&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">of a Person or entity means a corporation, partnership, limited liability company, or other business entity that is controlled by such Person or entity, and &#34;control&#34; has the meaning given to it in the definition of &#34;Affiliate.&#34;</font></div><div style="padding-left:75.6pt;padding-right:50.4pt"><font><br></font></div><div style="padding-left:75.6pt;padding-right:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Technology&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means the technology disclosed in the Licensed Patents. </font></div><div style="padding-right:50.4pt"><font><br></font></div><div style="padding-left:75.6pt;padding-right:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:232%">&#34;Territory&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:232%">means worldwide.</font></div><div style="padding-right:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#34;Valid Claim&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a valid, enforceable claim of an unexpired issued or granted Licensed Patent as long as the claim has not been admitted by Licensor or otherwise caused to be invalid or unenforceable through reissue, disclaimer, or otherwise, or held invalid or unenforceable.</font></div><div style="margin-top:12.3pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%;text-decoration:underline">Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%"> </font></div><div style="margin-top:11.15pt;padding-left:27pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%;text-decoration:underline">Patent License.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%"> During the Term of this Agreement, and subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, sublicensable right and license under the Licensed Patents to make, manufacture, produce, have made, use, offer to sell, sell, import, export, distribute, and otherwise research, develop, and commercialize Licensed Products and services in the Field of Use in the Territory.&#160;&#160;&#160;&#160;</font></div><div style="padding-right:10.8pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusivity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Other than as expressly set forth in this Agreement, Licensor</font></div><div style="padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(whether itself or through a third party) will not research, develop, commercialize, or otherwise practice or exploit the Technology in the Field of Use.</font></div><div style="margin-top:12.2pt;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;padding-left:5.4pt;text-decoration:underline">Sublicensing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font></div><div style="margin-top:12.2pt;padding-left:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Sublicense Grant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> Subject to the terms and conditions of this Agreement,</font></div><div style="margin-top:0.3pt;padding-left:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Licensor hereby grants to Licensee the right to sublicense all or any of its licensed rights to and under the Licensed Patents to a Sublicensee provided that such Sublicensee shall assume the same obligations and the same terms and conditions as Licensee hereunder&#59; and further provided that Licensee shall be responsible for the performance of all of such obligations, and for compliance with all of such terms and conditions, by Sublicensee. Licensee shall remain liable for the performance of all Licensee obligations under this Agreement and for the actions or inactions of any and all Sublicensees as if such actions or inactions were carried out by the Licensee itself.</font></div><div style="margin-top:14.05pt;padding-left:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Scope of Sublicense.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> No sublicense may exceed the scope of rights granted to</font></div><div style="margin-top:0.25pt;padding-left:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Licensee hereunder. Licensee shall require all sublicenses to be in writing and to include an agreement by the Sublicensee to be bound by the terms and conditions of this Agreement. </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.25pt;padding-left:21.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Each sublicense granted hereunder shall be consistent with and comply with all terms of this Agreement, shall incorporate terms and conditions sufficient to enable Licensee to comply with this Agreement, shall prohibit any further sublicense or assignment by a Sublicensee without Licensor consent and shall provide that Licensor is a third party beneficiary thereof (solely for purposes of enforcing its rights to any provisions which are for the benefit of Licensor and Indemnitees therein). Licensee shall provide to Licensor a fully executed copy of all sublicense agreements and amendments thereto, including all exhibits, attachments and related documents, within &#91;***&#93; of executing the same, provided that Licensee may redact financial and other sensitive business terms from such copy provided to Licensor. Upon termination or expiration of this Agreement for any reason, any sublicenses shall terminate effective as of the termination or expiration of this Agreement. Any sublicense which is not in accordance with the foregoing provisions shall be null and void.</font></div><div style="margin-top:12.05pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:5.4pt;text-decoration:underline">Improvements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> As between the Parties, each Party will solely own all right, title, and interest in and to any Improvement conceived or developed by its employees or independent contractors. Neither Party shall have any obligation to fund, finance, promote, or otherwise support the technology development of the other Party.</font></div><div style="margin-top:14.2pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;padding-left:5.4pt;text-decoration:underline">Royalties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font></div><div style="margin-top:11.75pt;padding-left:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">&#160;&#160;&#160;&#160;5.1&#160;&#160;&#160;&#160;Licensee shall pay to Licensor, during the Term, a royalty of &#91;***&#93; percent (&#91;*&#93;%) of Net Sales of Licensed Products sold by Licensee in a country where such Licensed Products are covered by a Valid Claim of a Licensed Patent in that country (&#34;Royalty&#34;).</font></div><div style="margin-top:0.45pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.1pt">Only one Royalty shall be paid for each instance of a Licensed Product. By way of example, whether the Licensed Product is covered by one (1) or more than one (1) Valid Claims of one (1) or more Licensed Patents, or by one (1) or more than one (1) claim Valid Claims of Licensed Patents in more than one (1) country.</font></div><div style="margin-top:13.75pt;padding-left:39.6pt;padding-right:10.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:18.42pt">Should Licensee grant any sublicenses, the terms and conditions of such sublicenses shall be in Licensee's sole discretion, provided that Royalties shall be paid by Licensee to Licensor in accordance with this Section 5 on Net Sales of all Licensed Products sold under such sublicenses where such Licensed Products are covered by a Valid Claim in the country in which the Licensed Product is sold. For the avoidance of doubt, a Sublicensee does not include any person or entity purchasing Licensed Products from Licensee, its Affiliate or its Sublicensee under a distributorship arrangement.</font></div><div style="margin-top:11.85pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.2&#160;&#160;&#160;&#160;Licensee shall pay the Royalty due under this Agreement for each Quarterly Period within &#91;***&#93; after the end of such Quarterly Period. During a Quarterly Period in which a Royalty payment is due, Licensee shall provide Licensor with GAAP-compliant financial statements showing, for the relevant Quarterly Period, the amount of Net Sales of Licensed Products by Licensee, or any Sublicensee, to any third party for the sale of Licensed Products, any deductions and offsets allocated with respect to such sale of Licensed Products, the calculation of Net Sales, and other information reasonably necessary for an accurate accounting of the payments due pursuant to this Agreement.</font></div><div style="margin-top:13.75pt;padding-left:10.8pt;padding-right:21.6pt;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">5.3&#160;&#160;&#160;&#160;If payments are not received by Licensor within &#91;***&#93; after the end of the relevant Quarterly Period, Licensee shall pay to Licensor interest on the overdue payment from that due date to the date of actual payment at a rate of &#91;***&#93; percent (&#91;**&#93;%) per </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.75pt;padding-left:10.8pt;padding-right:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">annum computed for the number of days actually elapsed and a year of three hundred sixty-five (365) days, or if lower, the maximum amount permitted under applicable Law.</font></div><div style="margin-top:12.15pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Records and Audit.</font></div><div style="margin-top:11.75pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Records.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensee shall keep and maintain complete and accurate records of its sales of Licensed Product necessary for the calculation of Royalties due to Licensor hereunder. Licensee shall maintain such records for the longer of&#58; (a) the period required by applicable law, or (b) &#91;***&#93; following the relevant Quarterly Period to which they pertain.</font></div><div style="margin-top:14.1pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Audit.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:11.4pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Licensor, at its sole cost and expense, may at any time within &#91;***&#93; after receiving any Royalty from Licensee, but no more frequently than annually, nominate an independent certified public accountant (&#34;Auditor&#34;) whom, upon reasonable written notice to Licensee and upon Licensee's approval, which approval shall not be unreasonably withheld, Licensee shall permit to have access to Licensee's records during Licensee's normal business hours for the sole purpose of verifying such Royalty payments made under this Agreement. In no event shall Licensor have the right to examine information with respect to Licensee's costs, BOM, pricing, or percentages of markup. As a condition to such access, Auditor shall execute a written agreement, satisfactory to the audited Party, obligating such accountant to maintain in strict confidence all information disclosed to such accountant pursuant to the examination.</font></div><div style="margin-top:14.15pt;padding-left:50.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Licensor shall provide to Licensee a copy of the Auditor's audit report within &#91;***&#93; of Licensor's receipt of the report. If the audit report shows that payments made by Licensee are deficient, Licensee shall pay Licensor the deficient amount within &#91;***&#93; after Licensee's receipt of the audit report inclusive of interest as defined in section 5.3 of this Agreement, as applicable. In the event the audit reveals an underpayment by Licensee of more than &#91;***&#93; percent (&#91;**&#93;%) of the Royalty amount due, Licensee will pay Licensor's actual and reasonable costs to the Auditor, such amounts are due within &#91;***&#93; of completion of the audit.</font></div><div style="margin-top:12.5pt;padding-left:3.6pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:1.8pt;text-decoration:underline">Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The Parties agree that Licensee shall provide to Licensor confidential progress reports setting out a high-level status update on the development and commercialization of Licensed Products as the Parties mutually deem appropriate on an annual basis, due &#91;***&#93; of each calendar year. Any such progress reports, and their contents, shall be deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">&#34;Confidential Information&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> and be subject to Section 11 of this Agreement.</font></div><div style="margin-top:13.8pt;padding-left:3.6pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:1.8pt;text-decoration:underline">Development and Commercialization.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> During the Term, Licensee or its Sublicensee will use commercially reasonable efforts to develop and commercialize Licensed Products in the Field of Use. Licensee shall be solely responsible for its costs and activities relating to the development of the Licensed Products, pre-clinical and clinical testing (as appropriate) of the Licensed Products, and preparation and filing of all documents required in connection with seeking and obtaining regulatory approval of Licensed Products in the Field of Use and in the Territory. Once regulatory approvals are gained, Licensee will be responsible for all sales, marketing, and distribution costs and related commercialization activities related to the Licensed Products.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14.1pt;padding-left:3.6pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:1.8pt;text-decoration:underline">Patent Prosecution and Maintenance.</font></div><div style="margin-top:11.95pt;padding-left:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Patent Prosecution and Maintenance by Licensor.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> For each patent and patent</font></div><div style="padding-left:25.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">application included within the Licensed Patents, Licensor is responsible for prosecuting all patent applications to issuance or final rejection at its own cost and expense. Any taxes, annuities, maintenance fees, renewal fees, and extension charges for each patent and patent application included within the Licensed Patents shall be timely paid by Licensor.</font></div><div style="margin-top:14.05pt;padding-left:50.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Patent Prosecution and Maintenance by Licensee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> If Licensor does not maintain</font></div><div style="padding-left:25.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">or prosecute any patent or patent application included within the Licensed Patents in a specific country or jurisdiction, or intends to allow any such patent or patent application to be abandoned, lapse, expire, or be cancelled, Licensee shall have the option to file, maintain, or prosecute such patent or patent application in that specific country or jurisdiction. Licensor shall immediately notify Licensee if any patent or patent application shall be abandoned, lapse, expire, be cancelled, or no longer pursued for any reason (including, for example, failure to respond to an Office Action, file an appeal, or pay an annuity or maintenance fee), and Licensee, in its sole discretion, may file, maintain, or prosecute any such patent or patent application, with such costs and expenses incurred by Licensee deductible from any Royalty payment due to Licensor. If Licensee desires that a corresponding patent application be filed in any jurisdiction claiming priority to one of the Licensed Patents, Licensee shall notify Licensor of that desire, and Licensor shall promptly notify Licensee if it will file such corresponding application. Failing such agreement, Licensor shall permit Licensee to file such patent application in the relevant specific country or jurisdiction only and to prosecute it to issuance or final rejection, with such costs and expenses incurred by Licensee deductible from any Royalty payment due to Licensor. Such patent application and any related patents will be added to Schedule A.</font></div><div style="margin-top:13.7pt;padding-left:10.8pt;padding-right:64.8pt;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">9.3&#160;&#160;&#160;&#160;At Licensee's request, Licensor shall consult with Licensee as to the preparation, filing, prosecution, and maintenance of the Licensed Patents.</font></div><div style="margin-top:12.8pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">, Third-Party Infringement Claims.</font></div><div style="margin-top:11.1pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notice of Infringement or Third-Party Claims.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> If (a) either Party believes that any Licensed Patent is being infringed or misappropriated by a third party in the Field of Use, or (b) if a third party alleges that any Licensed Patent is invalid or unenforceable, or claims that a Licensed Product, or its use, development, manufacture, or sale infringes such third party's intellectual property rights in the Field of Use, the Party possessing such belief or awareness of such claims shall promptly provide written notice to the other Party and provide it with all details of such infringement or claim, as applicable, that are known by such Party.</font></div><div style="margin-top:13.95pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Right to Bring Action or Defend.</font></div><div style="margin-top:11.6pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15.5pt">Licensor have the initial option to enforce its rights under any Licensed Patent, defend any declaratory judgment action concerning any Licensed Patent, and take any other lawful action reasonably necessary to protect, enforce, or defend any Licensed Patent, and control the conduct thereof and attempt to resolve any claims relating to any Licensed Patent, including by (a) prosecuting or defending any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">inter partes </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">review, post-grant review, covered business method patent review, opposition, derivation, interference, declaratory judgment, federal district court, U.S. Patent and </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.6pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Trademark Office, U.S. International Trade Commission, or other proceeding of any kind, and (b) taking any other lawful action that Licensor, in its sole discretion, believes is reasonably necessary to protect, enforce, or defend any Licensed Patent. Licensor shall bear its own costs and expenses in all such proceedings and have the right to control the conduct thereof and be represented by counsel of its own choice therein.</font></div><div style="margin-top:13.95pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.82pt">If Licensor chooses in its sole discretion not to enforce its rights under any of the Licensed Patents, it will timely notify Licensee in writing and Licensee has the option to enforce any rights under the Licensed Patents, at its own cost and expense and Licensee will be entitled to retain any damage award resulting from enforcement action.</font></div><div style="margin-top:13.5pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15.5pt">The Parties shall reasonably cooperate in the enforcement of any of the Licensed Patents, including without limitation, agreeing to be a named party to any action to enforce the Licensed Patents to the extent reasonably required, and executing such documents as may be reasonably necessary.</font></div><div style="margin-bottom:4.35pt;margin-top:12.05pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Recovery and Settlement.</font></div><div style="padding-left:50.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:8.3pt">If Licensor undertakes the enforcement or defense of any Licensed Patent, any recovery, damages, or settlement derived from such suit, action, or other proceeding will be retained in its entirety by Licensor&#59; and Licensor may settle any such suit, action, or other proceeding, whether by consent order, settlement, or other voluntary final disposition, without the prior written approval of Licensee, provided that Licensor shall not settle any such suit, action, or other proceeding in a manner that adversely affects the rights of Licensee concerning the Licensed Patents without Licensee's prior written consent, which consent may not be unreasonably withheld.</font></div><div style="margin-top:13.85pt;padding-left:50.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.62pt">If Licensee undertakes the enforcement or defense of any Licensed Patent, any recovery, damages, or settlement derived from such suit, action, or other proceeding will be retained in its entirety by Licensee&#59; and Licensee may only settle any such suit, action, or other proceeding, whether by consent order, settlement, or other voluntary final disposition, with the prior written consent of Licensor, which consent may not be unreasonably withheld.</font></div><div style="margin-top:12.1pt;padding-left:21.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">10.4 If any suit, action, or other proceeding alleging invalidity or non-infringement of any Licensed Patent is brought against Licensee or any Sublicensee, Licensor, at its option, will have the right, within &#91;***&#93; after written notice of commencement of such suit, action, or other proceeding, to intervene and take over the defense of the suit, action, or other proceeding at its own expense.</font></div><div style="margin-top:12.2pt;text-align:justify;text-indent:25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:31.8pt;text-decoration:underline">Recordation of License.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> If recordation of this Agreement or any part of it with a governmental authority is necessary for Licensee to fully enjoy the rights, privileges, and benefits of this Agreement, Licensee shall be permitted to record this Agreement or all such parts of this Agreement and information concerning the license granted hereunder with such appropriate governmental authority.</font></div><div style="margin-top:12.3pt;text-align:justify;text-indent:25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;padding-left:31.8pt;text-decoration:underline">Confidentiality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;padding-left:21.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">12.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Confidentiality Obligations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensor acknowledges that the information provided in Licensee's confidential progress reports under Section 7 and provided by the independent public accountant under Section 6.2, shall be Confidential Information of Licensee. As a condition to being provided with Confidential Information, Licensor, during the Term of this Agreement, shall&#58;</font></div><div style="margin-top:12pt;padding-left:50.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%;padding-left:8.3pt">not use the Confidential Information other than as strictly necessary to perform its obligations under this Agreement&#59; and</font></div><div style="margin-top:13.75pt;padding-left:50.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.62pt">maintain the Confidential Information in strict confidence and not disclose the Confidential Information without Licensee's prior written consent, provided, however, Licensor may disclose the Confidential Information to its Representatives who&#58;</font></div><div style="margin-top:11.85pt;padding-left:86.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(i)&#160;&#160;&#160;&#160;have a need to know the Confidential Information for purposes of Licensor's performance, or exercise of its rights concerning the Confidential Information, under this Agreement&#59;</font></div><div style="padding-left:75.6pt;text-indent:45.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:119%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:119%;padding-left:8.48pt">have been apprised of this restriction&#59; and</font></div><div style="margin-top:13.75pt;padding-left:75.6pt;padding-right:10.8pt;text-align:justify;text-indent:45.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:5.29pt">are themselves bound by written nondisclosure agreements at least as restrictive as those set forth in this Agreement.</font></div><div style="margin-top:12.1pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Licensor shall use reasonable care, at least as protective as the efforts it uses for its own confidential information, to safeguard the Confidential Information from use or disclosure other than as expressly permitted hereby.</font></div><div style="margin-top:12.2pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">12.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Exceptions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:11.8pt;padding-left:43.2pt;padding-right:32.4pt;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:19.66pt">If Licensor becomes legally compelled to disclose any Confidential Information, the Receiving Party shall&#58;</font></div><div style="margin-top:11.85pt;padding-left:75.6pt;padding-right:10.8pt;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(i) &#160;&#160;&#160;&#160;provide prompt written notice to the Disclosing Party so that the Disclosing Party may seek a protective order or other appropriate remedy or waive its rights under this section&#59; and</font></div><div style="margin-top:11.9pt;padding-left:75.6pt;padding-right:25.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;disclose only the portion of Confidential Information that it is legally required to furnish.</font></div><div style="margin-top:11.95pt;padding-left:39.6pt;padding-right:21.6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">If a protective order or other remedy is not obtained, or Licensee waives compliance under this section, Licensor shall, at Licensee's expense, use reasonable efforts to obtain assurance that confidential treatment will be afforded the Confidential Information.</font></div><div style="margin-top:12.25pt;padding-left:43.2pt;padding-right:10.8pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.01pt">Confidential Information does not include information that Licensor can demonstrate by documentary evidence&#58; (a) was already known to Licensor without restriction on use or disclosure prior to the receipt of such information directly or indirectly from or on behalf of Licensor&#59; (b) was or is independently developed by Licensor without reference to or use of any Confidential Information&#59; (3) was or becomes generally known by the public other than by breach of this Agreement by, or other wrongful act of, Licensor&#59; or (4) was received by Licensor from a third party who was </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12.25pt;padding-left:43.2pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">not, at the time, under any obligation to Licensee or any other Person to maintain the confidentiality of such information.</font></div><div style="margin-top:12.2pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Representations and Warranties.</font></div><div style="margin-top:11.9pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">13.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;text-decoration:underline">Mutual Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Each Party represents and warrants to the other party that as of the Effective Date&#58;</font></div><div style="padding-left:43.2pt;padding-right:10.8pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.66pt">it is duly organized, validly existing, and in good standing as a corporation or other entity as represented herein under the laws and regulations of its jurisdiction of incorporation, organization, or chartering&#59;</font></div><div style="padding-left:75.6pt;padding-right:10.8pt;text-align:justify"><font><br></font></div><div style="padding-left:43.2pt;padding-right:10.8pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:19.01pt">it has the full right, power, and authority to enter into this Agreement and to perform its obligations hereunder&#59;</font></div><div style="margin-top:14.05pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.66pt">the execution of this Agreement by its representative whose signature is set forth at the end hereof has been duly authorized&#59; and</font></div><div style="margin-top:14.05pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:115%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:19.01pt">when executed and delivered by such Party, this Agreement will constitute the legal, valid, and binding obligation of that Party, enforceable against that Party in accordance with its terms.</font></div><div style="margin-top:12.35pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Licensor Representations and Warranties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensor represents and warrants that&#58;</font></div><div style="padding-left:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%;padding-left:8.3pt">Licensor is the owner of the entire right, title, and interest in and to the Licensed Patents&#59;</font></div><div style="margin-top:0.4pt;padding-left:14.4pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:7.62pt">Licensor has the right and power to grant the licenses granted herein&#59; (c) Licensor has not granted to any third party any licenses or other rights under the Licensed Patents that are in conflict with the terms and conditions of this Agreement&#59; (d) to Licensor's knowledge, Licensor knows of no prior art that would invalidate the Licensed Patents&#59; and (e) the patents and patent applications identified on Schedule A are all the patents and patent applications owned by Licensor as of the Effective Date that are necessary for the manufacture, use, sale, offer for sale, or importation of any Licensed Products in the Field of Use in the Territory.</font></div><div style="margin-top:14.25pt;padding-left:14.4pt;padding-right:10.8pt;text-align:justify;text-indent:25.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">13.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Disclaimer.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, LICENSOR DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, WHETHER WRITTEN, ORAL, EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, CONCERNING THE VALIDITY, ENFORCEABILITY, AND SCOPE OF THE LICENSED PATENTS, THE ACCURACY, COMPLETENESS, SAFETY, USEFULNESS FOR ANY PURPOSE, OR LIKELIHOOD OF SUCCESS (COMMERCIAL, REGULATORY OR OTHER) OF THE LICENSED PRODUCTS, LICENSED KNOW-HOW, AND ANY OTHER TECHNICAL INFORMATION, TECHNIQUES, MATERIALS, METHODS, PRODUCTS, PROCESSES, OR PRACTICES AT ANY TIME MADE AVAILABLE BY LICENSOR, INCLUDING ALL IMPLIED WARRANTIES OF MERCHANTABILITY, QUALITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, AND WARRANTIES ARISING FROM A COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE, OR TRADE PRACTICE. WITHOUT LIMITATION TO THE FOREGOING, LICENSOR WILL HAVE NO LIABILITY WHATSOEVER TO LICENSEE OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY INJURY, LOSS, OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSESSED OR </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:14.25pt;padding-left:14.4pt;padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED ON LICENSEE OR ANY OTHER PERSON, ARISING OUT OF OR IN CONNECTION WITH OR RESULTING FROM (A) THE MANUFACTURE, USE, OFFER FOR SALE, SALE, OR IMPORT OF A LICENSED PRODUCT, OR THE PRACTICE OF THE LICENSED PATENTS&#59; (B) THE USE OF OR ANY ERRORS OF OMISSIONS IN ANY KNOW-HOW, TECHNICAL INFORMATION, TECHNIQUES, OR PRACTICES DISCLOSED BY LICENSOR&#59; OR (C) ANY ADVERTISING OR OTHER PROMOTIONAL ACTIVITIES CONCERNING ANY OF THE FOREGOING.</font></div><div style="margin-top:12.05pt;padding-left:14.4pt;padding-right:10.8pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Exclusion of Consequential and Other Indirect Damages.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> TO THE FULLEST EXTENT PERMITTED BY LAW, LICENSOR WILL NOT BE LIABLE TO LICENSEE OR ANY OTHER PERSON FOR ANY INJURY TO OR LOSS OF GOODWILL, REPUTATION, BUSINESS, PRODUCTION, REVENUES, PROFITS, ANTICIPATEDPROFITS, CONTRACTS, OR OPPORTUNITIES (REGARDLESS OF HOW THESE ARE CLASSIFIED AS DAMAGES), OR FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY, SPECIAL, PUNITIVE, OR ENHANCED DAMAGES WHETHER ARISING OUT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, PRODUCT LIABILITY, OR OTHERWISE (INCLUDING THE ENTRY INTO, PERFORMANCE, OR BREACH OF THIS AGREEMENT), REGARDLESS OF WHETHER SUCH LOSS OR DAMAGE WAS FORESEEABLE OR THE PARTY AGAINST WHOM SUCH LIABILITY IS CLAIMED HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSS OR DAMAGE, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED OR OTHER REMEDY OF ITS ESSENTIAL PURPOSE.</font></div><div style="margin-top:14.15pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:10.2pt;text-decoration:underline">Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="margin-top:11.45pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Licensee Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensee shall indemnify, defend, and hold harmless Licensor and its officers, directors, employees, agents, successors, and assigns against all losses arising out of or resulting from&#58; (a) any third party claim, suit, action, or other proceeding related to or arising out of or resulting from Licensee's breach of any representation, warranty, covenant, or obligation under this Agreement, (b) any claim, demand, suit, proceeding, investigation, or other action of any nature related to any Licensed Product as manufactured, sold or distributed by Licensee, or a Sublicensee or Affiliate thereof, or (c) any claim, demand, suit, proceeding, investigation, or other action of any nature relating to or arising out of Licensee's action or inaction prior to or after the Effective Date .</font></div><div style="margin-top:13.6pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">15.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Licensor Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensor shall indemnify, defend, and hold harmless Licensee and its officers, directors, members, managers, employees, agents, and representatives from and against any and Claims to the extent arising out of or resulting from (a) any representation or warranty by Licensor set forth herein being untrue in any material respect when made or any material breach or material default by Licensee of any of its covenants or other obligations hereunder&#59; (b) any claim, demand, suit, proceeding, investigation, or other action of any nature related to any Licensor intellectual property&#59; or (c) any claim, demand, suit, proceeding, investigation, or other action of any nature relating to or arising out of Licensor's action or inaction prior to or after the Effective Date.</font></div><div style="margin-top:12.45pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:116%;padding-left:10.2pt;text-decoration:underline">Term and Termination.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.7pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">16.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Term.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement is effective as of the Effective Date and will continue in full force and effect until the expiry of the last patent of the Licensed Patents to terminate, whether through expiration, abandonment, lapse, or otherwise, unless earlier terminated by either Party as permitted by this Agreement (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">&#34;Term&#34;).</font></div><div style="margin-top:13.6pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">16.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Licensor Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Licensor may terminate this Agreement upon &#91;***&#93; written notice to Licensee if&#58;</font></div><div style="margin-bottom:19.85pt;margin-top:11.8pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Licensee fails to pay any amount due under this Agreement on the due date for payment and remains in default not less than &#91;***&#93; after </font></div><div style="padding-right:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">Licensor's written notice to make such payment, including the payment of interest in accordance with Section 5.3&#59;</font></div><div style="margin-top:13.7pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%;padding-left:19.01pt">Licensee materially breaches this Agreement (other than through a failure to pay any amounts due under this Agreement) and, if such breach is curable, fails to cure such breach within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">of Licensor's written notice of such breach&#59; or</font></div><div style="margin-top:13.85pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:19.66pt">Licensee&#58; (i) is dissolved or liquidated or takes any corporate action for such purpose&#59; (ii) becomes insolvent or is generally unable to pay, or fails to pay, its debts as they become due&#59; (iii) files or has filed against it a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law&#59; (iv) makes or seeks to make a general assignment for the benefit of creditors&#59; or (v) applies for or has a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.</font></div><div style="margin-top:13.65pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%;padding-left:19.01pt">Licensee or any Affiliate or Sublicensee directly or indirectly challenges the validity or ownership of any of the Licensed Patents and does not cease such challenge within </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">of receipt of notice thereof from Licensor.</font></div><div style="margin-top:11.85pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">16.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%;text-decoration:underline">Licensee Right to Terminate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%"> Licensee shall have the right to terminate this Agreement for any reason at any time upon </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%">&#91;***&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">written notice to Licensor.</font></div><div style="margin-top:14.05pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">16.4 The Parties acknowledge and agree that the licenses granted by the Parties and all other rights granted under or pursuant to this Agreement are, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to &#34;intellectual property&#34; as defined under Section 101 of the Bankruptcy Code (or analogous foreign provisions), and that this Agreement is an executory contract governed by Section 365(n). In the event of Licensor's bankruptcy or insolvency, unless expressly terminated by Licensee, this Agreement shall continue under section 365(n) of the U.S. Bankruptcy Code, and Licensee shall be entitled to all rights and benefits afforded by such section, including the right to elect to continue to perform all of the obligations under this license and to retain the intellectual property licensed hereunder.</font></div><div style="margin-top:12.45pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%">16.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:118%;text-decoration:underline">Effect of Expiration or Termination.</font></div><div style="margin-top:11.7pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:19.66pt">Upon the expiration of this Agreement in any country in the Territory, the licenses granted to Licensee under this Agreement will become fully paid, perpetual, and irrevocable in such country.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:13.3pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:122%;padding-left:19.01pt">Upon any termination of this Agreement, other than as provided under Section 16.3&#58;</font></div><div style="margin-bottom:19.9pt;margin-top:11.9pt;padding-left:147.6pt;padding-right:10.8pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%;padding-left:25.17pt">Licensee shall immediately cease exercising all rights granted under the Licensed Patents&#59;</font></div><div style="margin-top:0.55pt;padding-left:75.6pt;padding-right:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:17.76pt">Each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party's possession or control containing the other Party's Confidential Information&#59; and</font></div><div style="margin-top:13.95pt;padding-left:75.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;padding-left:14.43pt">All sublicenses granted by Licensee will automatically terminate.</font></div><div style="margin-top:12.3pt;padding-left:75.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">(c)&#160;&#160;&#160;&#160;Expiration or termination of this Agreement will not relieve the Parties</font></div><div style="margin-top:0.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">of any obligations accruing before the Effective Date of expiration or termination.</font></div><div style="margin-top:12.25pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">16.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The rights and obligations of the Parties set forth in this Section 16 and Section 1 (Definitions), Section 12 (Confidentiality), Section 13 (Representations and Warranties), Section 14 (Damages), Section 15 (Indemnification), and Section 17 (Miscellaneous) will survive any such termination or expiration.</font></div><div style="margin-top:12.25pt;padding-left:10.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">17. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%;text-decoration:underline">Miscellaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%"> </font></div><div style="margin-top:12.1pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Force Majeure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Neither Party will be in default by reason of any failure or delay in the performance of its obligations hereunder where such failure or delay is due to any circumstance or cause beyond such Party's reasonable control, including strikes, labor disputes, civil disturbances, riot, rebellion, invasion, epidemic, hostilities, war, terrorist attack, embargo, natural disaster, acts of God, flood, sabotage, or fire.</font></div><div style="margin-top:13.8pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Further Assurances.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Each Party shall, upon the reasonable request, and at the sole cost and expense, of the other party, promptly execute such documents and take such further actions as may be necessary to give full effect to the terms of this Agreement.</font></div><div style="margin-top:14.05pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.3 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Independent Contractors.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The relationship between the Parties is that of independent contractors. Nothing contained in this Agreement creates any agency, partnership, joint venture, or other form of joint enterprise, employment, or fiduciary relationship between the Parties, and neither Party has authority to contract for or bind the other party in any manner whatsoever.</font></div><div style="margin-top:13.75pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.4 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">No Public Statements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Neither Party may issue or release any public announcement, statement, press release, or other publicity concerning this Agreement without the prior written consent of the other Party. Notwithstanding the foregoing, either Party may disclose the nature and existence of this Agreement to the extent required by law or to allow such Party to exercise its rights under the Agreement.</font></div><div style="margin-bottom:75.35pt;margin-top:13.75pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.5 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> All notices, requests, consents, claims, demands, waivers, and other communications hereunder must be in writing and sent to the respective Party at the addresses indicated below (or at such other address for a Party as may be specified in a notice given in accordance with this section)&#58;</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="padding-right:10.8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:66.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:49.45pt;margin-top:6.35pt;padding-right:83.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Licensor&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Kiora Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">332 Encinitas Blvd, Suite 102</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encinitas, CA 92024</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Brian Strem, President &#38; CEO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Email&#58; bstrem&#64;kiorapharma.com</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">If to Licensee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:19.85pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Sentrx Animal Care, Inc.</font></div><div style="margin-top:0.25pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">570 West 1700 South, Suite 1400</font></div><div style="margin-top:0.3pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Salt Lake City, Utah 84115</font></div><div style="margin-top:0.4pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Attention&#58; Brian Segebrecht, President &#38; CEO</font></div><div style="margin-top:0.1pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Email&#58; bsegebrecht&#64;sentrxanimalcare.com</font></div></td></tr></table></div><div style="padding-right:10.8pt;text-align:justify"><font><br></font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:3.6pt;text-indent:18pt"><font><br></font></div><div style="margin-top:0.1pt;padding-left:18pt;padding-right:3.6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:113%">Notices sent in accordance with this section will be deemed effective&#58; (a) when received, if delivered by hand (with written confirmation of receipt)&#59; (b) when received, if sent by a nationally recognized overnight courier (receipt requested)&#59; or (c) on the date sent by email, if sent during normal business hours of the recipient, and on the next business day if sent after normal business hours of the recipient.</font></div><div style="margin-top:12.2pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.6 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Interpretation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> For purposes of this Agreement&#58; (a) the words &#34;include,&#34; &#34;includes,&#34; and &#34;including&#34; will be deemed to be followed by the words &#34;without limitation&#34;&#59; (b) the word &#34;or&#34; is not exclusive&#59; and (c) the words &#34;herein,&#34; &#34;hereof,&#34; &#34;hereby,&#34; &#34;hereto,&#34; and &#34;hereunder&#34; refer to this Agreement as a whole. This Agreement will be construed without regard to any presumption or rule requiring construction or interpretation against the Party drafting an instrument or causing any instrument to be drafted.</font></div><div style="margin-top:13.7pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.7 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Headings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> The headings in this Agreement are for reference only and do not affect the interpretation of this Agreement.</font></div><div style="margin-top:14pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement, together with all Schedules and any other documents incorporated herein by reference, constitutes the sole and entire agreement of the Parties with respect to the subject matter contained herein, and supersedes all prior and contemporaneous understandings and agreements, both written and oral, with respect to such subject matter.</font></div><div style="margin-top:14pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.9 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Assignment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Neither Party may assign the Agreement or the rights and obligations thereunder to any third party without the prior express written approval of the other Party. Notwithstanding the foregoing, if the Agreement is assigned to an Affiliate of a Party, or the Assignment is in connection with a merger or sale of substantially all the assets of a Party, no prior express written approval of the other Party is required.</font></div><div style="margin-top:12.25pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.10 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">No Third-Party Beneficiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement is for the sole benefit of the Parties and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or will confer upon any other Person or entity any legal or equitable right, benefit, or remedy of any nature whatsoever, under or by reason of this Agreement.</font></div><div style="margin-top:13.85pt;padding-left:18pt;padding-right:3.6pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.11 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;text-decoration:underline;top:-4.2pt;vertical-align:baseline">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">, Modification&#59; Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement may only be amended, modified, or supplemented by an agreement in writing signed by each Party. No waiver by</font></div><div style="padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">any Party of any of the provisions hereof will be effective unless explicitly set forth in writing and signed by the waiving Party. Except as otherwise set forth in this Agreement, no failure to </font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="padding-right:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">exercise, or delay in exercising, any rights, remedy, power, or privilege arising from this Agreement will operate or be construed as a waiver thereof&#59; nor will any single or partial exercise of any right, remedy, power, or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power, or privilege.</font></div><div style="margin-top:13.75pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> If any term or provision of this Agreement is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or unenforceability will not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. Upon a determination that any term or other provision is invalid, illegal, or unenforceable, the Parties shall negotiate in good faith to modify this Agreement so as to give effect to the original intent of the Parties as closely as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible.</font></div><div style="margin-top:14pt;padding-left:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.13 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Governing Law&#59; Submission to Jurisdiction.</font></div><div style="margin-top:11.7pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:15.5pt">This Agreement and all related documents, and all matters arising out of or relating to this Agreement, are governed by, and construed in accordance with, the laws of the State of Delaware, United States of America, without regard to the conflict of laws provisions thereof to the extent such principles or rules would require or permit the application of the laws of any jurisdiction other than those of the State of Delaware.</font></div><div style="margin-top:12.05pt;padding-left:39.6pt;padding-right:10.8pt;text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;padding-left:14.82pt">Any action, suit, or other proceeding arising out of or related to this Agreement, the licenses granted hereunder, the validity or enforceability or scope of any Licensed Patent claim, whether a product infringes a Valid Claim, any challenges to a Licensed Patent, or Licensor's or Licensee's obligations concerning the Licensed Patents must be instituted exclusively in the federal courts of the United States or the courts of the State of Delaware, and each Party irrevocably submits to the exclusive jurisdiction of such courts in any such suit, action, or proceeding. Service of process, summons, notice, or other document by mail to such Party's address set forth herein will be effective service of process for any action, suit, or other proceeding brought in any such court.</font></div><div style="margin-top:11.7pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.14 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Equitable Relief.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> Each Party acknowledges that a breach by the other Party of the confidentiality provisions of this Agreement may cause the non-breaching Party irreparable harm, for which an award of damages would not be adequate compensation and, in the event of such a breach or threatened breach, the non-breaching Party will be entitled to seek equitable relief, including in the form of a restraining order, orders for preliminary or permanent injunction, specific performance, and any other relief that may be available from any court. These remedies are not exclusive but are in addition to all other remedies available under this Agreement at law or in equity, subject to any express exclusions or limitations in this Agreement to the contrary.</font></div><div style="margin-top:11.95pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.15 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Attorneys' Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> In the event that any action, suit, or other legal or administrative proceeding is instituted or commenced by either Party against the other Party arising out of or related to this Agreement, the prevailing Party will be entitled to recover its reasonable attorneys' fees and court costs from the non-prevailing Party.</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="margin-top:11.9pt;padding-left:10.8pt;padding-right:10.8pt;text-align:justify;text-indent:28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">17.16 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;text-decoration:underline">Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> This Agreement may be executed in counterparts, each of which will be deemed an original, but all of which together will be deemed to be one and the same agreement. A signed copy of this Agreement delivered by email, or other means of electronic transmission (to which assigned PDF copy is attached) will be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.</font></div><div style="margin-bottom:512.6pt;margin-top:12.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:114%">&#91;SIGNATURE PAGE FOLLOWS&#93;</font></div><div style="margin-bottom:512.6pt;margin-top:12.25pt"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="padding-right:10.8pt;text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><div id="i53841b04ae5e4d2ea079a1f72f29ab57_25"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:14.2pt;padding-left:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first above written</font></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:41.481%"><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Kiora Pharmaceuticals, Inc.</font></div><div style="margin-top:14.65pt;padding-right:-39.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Brian M. Strem, Ph.D.</font></div><div style="margin-top:11.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Brian M Strem, PhD</font></div><div><font><br></font></div><div style="margin-top:3.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%">President &#38; CEO </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">12 June 2023 </font></div><div style="margin-bottom:4.85pt"><font><br></font></div><div style="margin-bottom:4.85pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sentrx Animal Care, Inc.</font></div><div style="margin-top:14.65pt;padding-right:-39.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Signature&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Brian Segebrecht</font></div><div style="margin-top:11.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Name&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:120%"> Brian Segebrecht</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">President &#38; CEO </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">12 June 2023 </font></div></div><div style="display:inline-block;max-width:17.037%;min-width:16.037%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:41.482%"></div></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><div id="i53841b04ae5e4d2ea079a1f72f29ab57_34"></div><hr style="page-break-after:always"><div style="min-height:67.68pt;width:100%"><div><font><br></font></div></div><div style="margin-top:0.45pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:118%">SCHEDULE A</font></div><div style="margin-bottom:13pt;margin-top:11.4pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:130%">The following patents and patent applications, and (i) any patents and applications that claim priority to or the benefit of such patents and applications, (ii) any patents that issue therefrom, (iii) any continuation, continuation-in-part, divisional, extension, substitution, reissue, re-examination, and renewal of any of the foregoing, and (iv) any related, corresponding, or foreign counterpart applications and patents.</font></div><div style="padding-left:1.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:31.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:104%">Serial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:104%">#&#47;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Filing Date&#47;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Description</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Patent #</font></td><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Issue Date</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 13.95pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 12.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-left:0.75pt solid #000000;border-right:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 11.8pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:21.1pt"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>exhibit991-pressreleasejun.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia758d8dee044410a8d0cba4d25e07a0f_1"></div><div style="min-height:76.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="margin-top:10pt;text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201 </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary use</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kiora will receive a royalty on net sales of products covered by licensed patents</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ&#58; KPRX) (&#34;Kiora&#34;) and Sentrx Animal Care (&#34;Sentrx&#34;) announced today they have amended their existing licensing agreement for patents and technology related to Kiora's KIO-201 product candidate. The amended agreement between the companies eliminates up to $4.75M in near-term financial payments by Kiora to Sentrx that would have been required under the original license agreement signed in 2018&#59; grants Sentrx an exclusive license to certain patents, related to the combination use of the hyaluronic acid technology used in KIO-201 with antibiotics for development and commercialization in the field of animal health&#59; provides Kiora with a low single-digit royalty on Sentrx net sales in animal health of products protected by certain patents owned by Kiora&#59; and maintains Kiora's optionality to source alternative manufacturing partners for KIO-201.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;Amending this agreement has been a corporate goal since joining Kiora,&#34; said Brian Strem, Ph.D., President &#38; CEO of Kiora. &#34;The new structure benefits both companies. It provides us with greater financial flexibility to invest in our development pipeline, and offers Sentrx access to valuable patented technologies for veterinary use.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#34;This agreement strengthens our proprietary position for our pipeline of innovation in the veterinary ophthalmology space,&#34; said Brian Segebrecht, MBA, President &#38; Chief Executive Officer of Sentrx Animal Care. &#34;Kiora's patents, including those allowing for antibiotics to be combined with the cross-linked hyaluronic acid technology used in both KIO-201 and our BioHAnce&#8482; products, address an important need for innovation in companion animal eye care.&#34;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KIO-201 is a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. Kiora is currently developing KIO-201 for the treatment of persistent corneal epithelial defects (PCEDs). PCEDs are a rare disease where a patient's corneal wounds are resistant to standard treatment options and can lead to vision loss. Sentrx is leveraging similar technologies to KIO-201 in its BioHAnce&#8482; line of veterinary products.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Kiora Pharmaceuticals</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and&#47;or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (OPRA). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to news releases and SEC filings, Kiora expects to post information on its website, www.kiorapharma.com, and social media accounts that could be relevant to investors. Kiora encourages investors to follow Kiora on Twitter and LinkedIn as well as to visit its website and&#47;or subscribe to email alerts.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:76.5pt;width:100%"><div style="margin-top:10pt;text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Sentrx Animal Care</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sentrx is a Salt Lake City-based animal health company that was founded on exclusive, worldwide rights to BioHAnce&#8482; technology. This patented and proprietary technology uses advanced bioengineering to create a molecular matrix of crosslinked hyaluronic acid (HA) that produces a cellular scaffolding with unique physical and chemical properties. Sentrx transforms complex biotechnologies into easy-to-use care solutions that promote the long-term well-being of animals. Sentrx develops and manufactures veterinary ophthalmic and wound care products for companion animals.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#333333;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the statements in this press release are &#34;forward-looking&#34; and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These &#34;forward-looking&#34; statements include statements relating to, among other things, the ability of KIO-301 to restore visual function in patients with retinitis pigmentosa, the potential for KIO-301 to address other eye diseases, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-201, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the ability to conduct clinical trials on a timely basis, market and other conditions and certain risk factors described under the heading &#34;Risk Factors&#34; contained in Kiora's Annual Report on Form 10-K filed with the SEC on March 23, 2023 or described in Kiora's other public filings. Kiora's results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact</font></div><div style="margin-top:3pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Francina Agosti, Ph.D.</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(617) 546-0742</font></div><div><font style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">francina&#64;reportablenews.com</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>kprx-20230612.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:3fc74ccf-9297-43b4-8bd6-d0324616345f,g:2a091e00-480d-4af7-9ce8-bab735938b6e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:kprx="http://www.eyegatepharma.com/20230612" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.eyegatepharma.com/20230612">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230612_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="kprx-20230612_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.eyegatepharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>kprx-20230612_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:3fc74ccf-9297-43b4-8bd6-d0324616345f,g:2a091e00-480d-4af7-9ce8-bab735938b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f3140cee-703b-40e7-b991-9273a2541cce_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_0520d0e7-ab6c-4949-8fa2-6ff3bc08be82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8efb89e7-d478-493c-9643-ad1edbd57aa4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3120c20a-175c-4dcf-84d6-a43e6dae8f4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_2c4f4c6f-f9e8-4e85-bfbe-93b3e7402043_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fc5c84a7-98d5-4dc8-891e-00daab3ce6c5_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_6d158b20-def0-4248-8cc5-72f0fc1ad9d5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b2b7422b-d804-4714-b9a3-acbf87dbe31e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_67765ba6-066a-4ddb-ac71-dac8edf5e941_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_de3c2148-b04b-4a33-81a4-e2f248c176a7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ff1f29e7-5031-4143-8925-bcba7e80e31c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_52983c2c-2d29-493d-8a15-3b5fe5029105_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_90a7af6a-97dd-4502-9713-effeb64af715_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6d35a7ba-f711-4e56-b26d-52788c6ad1aa_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_ff9a03e1-27d2-44ea-ab85-5119732bca67_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5a9090ca-e879-4020-9308-d673dce11c85_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0a1582ee-3f34-46cb-94d8-c26c88be9fd8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_70a3b8cd-b669-43b5-8273-d39d191fb66c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_262c15cd-df92-4912-b845-0e75da77723a_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6d04539e-5a68-42c2-bd38-6e0bea0acff4_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_93fba88b-d85b-4ca7-9d46-29742b86116b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3b8d08f4-b37d-478f-94a6-086356e4b8da_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0cf603f6-565b-4ef6-87eb-d88a4e3e1012_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_459fd0ef-c4d3-48f0-9cb1-e815afb94c15_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>kprx-20230612_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:3fc74ccf-9297-43b4-8bd6-d0324616345f,g:2a091e00-480d-4af7-9ce8-bab735938b6e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.eyegatepharma.com/role/Cover" xlink:type="simple" xlink:href="kprx-20230612.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.eyegatepharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9c67575d-d186-4617-9e01-ed9264a839c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_DocumentType_9c67575d-d186-4617-9e01-ed9264a839c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7410503d-ad22-42e1-af57-fc74d6779073" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_DocumentPeriodEndDate_7410503d-ad22-42e1-af57-fc74d6779073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ab1b3dd5-98e2-4d5b-a875-c184f4810c0a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityRegistrantName_ab1b3dd5-98e2-4d5b-a875-c184f4810c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_cc745249-5299-4dcd-8771-82e556dae968" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_cc745249-5299-4dcd-8771-82e556dae968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ac78e21f-7d12-415e-a329-1d37676749cd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityTaxIdentificationNumber_ac78e21f-7d12-415e-a329-1d37676749cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_642c7bac-5979-42a5-baa3-41bbc46452da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityFileNumber_642c7bac-5979-42a5-baa3-41bbc46452da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_90c06695-f422-4f1f-96b7-905776ac1980" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityAddressAddressLine1_90c06695-f422-4f1f-96b7-905776ac1980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_0da06507-be64-4bf5-b4b2-6ccef6350d9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityAddressAddressLine2_0da06507-be64-4bf5-b4b2-6ccef6350d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b8de47ab-344d-49e2-9c0c-4cd195087157" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityAddressCityOrTown_b8de47ab-344d-49e2-9c0c-4cd195087157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_80f8836c-ae55-465d-af4e-7dd4b1764134" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityAddressStateOrProvince_80f8836c-ae55-465d-af4e-7dd4b1764134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_2a21e0cd-8d0c-4cef-9121-b3395ad84839" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityAddressPostalZipCode_2a21e0cd-8d0c-4cef-9121-b3395ad84839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_7928160c-351f-4187-a57d-4e69dbea31d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_CityAreaCode_7928160c-351f-4187-a57d-4e69dbea31d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9fbe71a7-cf62-45e4-8e7e-9ddb88cff2d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_LocalPhoneNumber_9fbe71a7-cf62-45e4-8e7e-9ddb88cff2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2fb45900-d725-4eee-8a14-371670e35fb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_WrittenCommunications_2fb45900-d725-4eee-8a14-371670e35fb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_00ea8135-9592-4987-b43c-01fe1275f5df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_SolicitingMaterial_00ea8135-9592-4987-b43c-01fe1275f5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b29aa2c9-4248-4c37-9c37-7a29e75fbd26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_PreCommencementTenderOffer_b29aa2c9-4248-4c37-9c37-7a29e75fbd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_110f3f94-151c-433c-b8cb-8856b5eb24e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_110f3f94-151c-433c-b8cb-8856b5eb24e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5b9abc1b-8f1c-4cdc-b0a6-fe5d7c13b22a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_Security12bTitle_5b9abc1b-8f1c-4cdc-b0a6-fe5d7c13b22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_95c5d3b8-d544-41ad-b935-d7e8d573ec46" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_TradingSymbol_95c5d3b8-d544-41ad-b935-d7e8d573ec46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_ae3f1346-1591-4892-845e-05b3607fdf39" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_SecurityExchangeName_ae3f1346-1591-4892-845e-05b3607fdf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a4564e69-d7d3-4787-b4be-f3e937c87fc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityEmergingGrowthCompany_a4564e69-d7d3-4787-b4be-f3e937c87fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d905f251-de4c-4c64-bc7c-83b67d26dad0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_EntityCentralIndexKey_d905f251-de4c-4c64-bc7c-83b67d26dad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4631407c-a879-478e-8a5e-6215c21ab7e7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_AmendmentFlag_4631407c-a879-478e-8a5e-6215c21ab7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5aa3a71b-180c-4046-983c-9b283beda6dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7caf5390-e449-40da-b96d-900896b29ea0" xlink:to="loc_dei_CurrentFiscalYearEndDate_5aa3a71b-180c-4046-983c-9b283beda6dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140028545791600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 12,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">KIORA PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0443284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">332 Encinitas Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Encinitas<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">224-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">KPRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>kprx-20230612_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="kprx-20230612.xsd" xlink:type="simple"/>
    <context id="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001372514</identifier>
        </entity>
        <period>
            <startDate>2023-06-12</startDate>
            <endDate>2023-06-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8yLTEtMS0xLTQyNjE4_7b264685-00de-4646-a1df-923c26d6f57a">0001372514</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF80L2ZyYWc6MTQzMTA2ODI5ZWI4NGMzZTlhNjZiMDA4ZTExYmFiODAvdGFibGU6NGQ5NWIwYTFiYWJkNDRhYWFhMThkZWVkZGM1NjhkNTUvdGFibGVyYW5nZTo0ZDk1YjBhMWJhYmQ0NGFhYWExOGRlZWRkYzU2OGQ1NV8zLTEtMS0xLTQyNjE4_7d56551b-53f4-492d-a437-f9a508398aa2">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzAy_2bff1795-c87e-4f86-bbcb-c11654d6491c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8yMjM_be48fbeb-c8ea-4c38-b45e-e6fdd44b8702">2023-06-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA2_2dd9dadd-e5aa-48da-a73b-11abc7b7f979">KIORA PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEy_b1d77c16-852d-4f08-b11a-c3a30845949e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTAtMS0xLTQyNjE4_e7ce04dd-1eb2-4154-8069-abbbefa40d30">001-36672</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6MWIzNzU5MDZmNTkxNDczYmFlZDgyOGViNmJhNGM1Y2UvdGFibGVyYW5nZToxYjM3NTkwNmY1OTE0NzNiYWVkODI4ZWI2YmE0YzVjZV8wLTEtMS0xLTQyNjE4_bf1d6144-4b1a-4c4e-b5aa-b5915a26affc">98-0443284</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA0_5ee33721-e45c-4ec6-80d3-395bd099bc34">332 Encinitas Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzEw_4c5543f0-af57-491f-a1b8-4f1ba5a2e993">Suite 102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE1_b8bde44d-1966-496a-bb0a-af429d61caba">Encinitas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA5_d5605d37-18e3-4783-bd6c-0f570906d767">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTQ_91c418b4-3997-45d6-8985-e661891ca6c8">92024</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV80MTg_54acb35f-46f3-4dbc-9aeb-d5e555f5a093">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzA1_7384835e-f3ab-46a9-863a-15f0599c0407">224-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8wLTAtMS0xLTQyNjE4_8dbffde0-b9ff-40fc-a2b5-eaf16deeb473">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl8yLTAtMS0xLTQyNjE4_3f1eb3a8-f9bb-4d0f-9005-e49663e06f39">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl80LTAtMS0xLTQyNjE4_71300be7-f4cf-4452-949d-597e4d487e38">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6Njg2NjU2YTI1OGNjNDc4ZTk4OWU3NGU3ODFhNmIwODYvdGFibGVyYW5nZTo2ODY2NTZhMjU4Y2M0NzhlOTg5ZTc0ZTc4MWE2YjA4Nl82LTAtMS0xLTQyNjE4_38d1facc-cc25-48a7-99e2-3b537510de13">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTAtMS0xLTQyNjE4_761545d6-2971-45eb-a8df-f19c596fe894">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTItMS0xLTQyNjE4_07eac58d-657c-4d9d-967f-fd27060c73f0">KPRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGFibGU6NDNlN2ViNjEwMzM4NDJjYzhiZmM1MjNiNjIxMWE1ODMvdGFibGVyYW5nZTo0M2U3ZWI2MTAzMzg0MmNjOGJmYzUyM2I2MjExYTU4M18xLTQtMS0xLTQyNjE4_decc6269-0e76-49cc-885d-e4ebf2cda371">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMzE2_5f3bf06b-3061-4b61-985f-a57b794662e4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany
      contextRef="i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612"
      id="id3VybDovL2RvY3MudjEvZG9jOjUwZjljMzIxNDczZjQyZjY5OWFiNmZmYjgxZmZkMWE4L3NlYzo1MGY5YzMyMTQ3M2Y0MmY2OTlhYjZmZmI4MWZmZDFhOF8xL2ZyYWc6NGJjYTBkOGQ3OWFmNDNkN2I4MWYyNTJlNWEwYjA0NDEvdGV4dHJlZ2lvbjo0YmNhMGQ4ZDc5YWY0M2Q3YjgxZjI1MmU1YTBiMDQ0MV8xMjk5_5f3bf06b-3061-4b61-985f-a57b794662e4">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %R'SU8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !<A\]6:E(TW^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M:L,P#(=?9?B>*'](&";U9:6G#08K;.QF;+4UBV-C:R1]^R5>FS*V!]C1TL^?
M/H$ZY;ER 9^#\QC(8+R;;#]$KOR&G8@\!XCJA%;&?$X,<_/@@I4T/\,1O%0?
M\HA0%44+%DEJ21(68.97(A.=5EP%E.3"!:_5BO>?H4\PK0![M#A0A#(O@8EE
MHC]/?0<WP (C##9^%U"OQ%3]$YLZP"[)*9HU-8YC/M8I-^]0PMO3XTM:-S-#
M)#DHG']%P^GL<<.NDU_KA^U^QT155'56M%G9[*N"-_>\:=\7UQ]^-V'KM#F8
M?VQ\%10=_+H+\0502P,$%     @ 7(?/5IE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( %R'SU8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 7(?/5FI2--_O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 7(?/5IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !=
MA\]6:;M/DUL$   :$0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ 78?/5I^@&_"Q @  X@P   T
M         ( !GPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !=A\]6EXJ[
M',     3 @  "P              @ %[#P  7W)E;',O+G)E;'-02P$"% ,4
M    " !=A\]6JL0B%C,!   B @  #P              @ %D$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ 78?/5B0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ 78?/5F60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="kprx-20230612.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eyegatepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="kprx-20230612.htm">kprx-20230612.htm</File>
    <File>exhibit101.htm</File>
    <File>exhibit102.htm</File>
    <File>exhibit991-pressreleasejun.htm</File>
    <File>kprx-20230612.xsd</File>
    <File>kprx-20230612_lab.xml</File>
    <File>kprx-20230612_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "kprx-20230612.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "kprx-20230612.htm"
     ]
    },
    "labelLink": {
     "local": [
      "kprx-20230612_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "kprx-20230612_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "kprx-20230612.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "kprx",
   "nsuri": "http://www.eyegatepharma.com/20230612",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230612.htm",
      "contextRef": "i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.eyegatepharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "kprx-20230612.htm",
      "contextRef": "i1dae0cffe7ba4799a527dae2c57b0859_D20230612-20230612",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.eyegatepharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001372514-23-000101-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001372514-23-000101-xbrl.zip
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ME3,8 (G.#^^V?_EY_^A-K;?NM0\:S+>=RF6X<7@5Z.!OB45X)R.F: =(+XR
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M 0:XX!K+@!4W$Q@T>\%3=(#>P"-A96XEAR+2&!04=IAJN*@LQ:I8&V_LMXH
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M6>%&D4#PG;M9ZNL!*DM_V6)+) I+->T6@UF9254^2;724^@$ =6N:(1!,JM
M2H'D4DZ.T%=X5DJXV9'^RD=DN'T@<?#PLAWO9GIZ+9Z81FC$UUX"3#*M0;24
M]DG'!CQEDP=_)&\]>=?"TR?9840._94!G- )['.9W(0F/J O"Q=:\T8RC;Q;
M9;G1*\Y@!,(AJZ):L.ZDBUW=50(!96BGV&+FJCUNF[9B@?M2)/SH'("#YN<
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MV>-!_^WPC#[CH\?'%Q\'XN*4+N4I#T[$QSX\^A*>AM_VCX^O1OWC/W%D>/@
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M"T**IDF^,]/K#G,K92S9L41F8B3S>:%BDG(Z&DH8$ FZ#Y[5:<;<:QY2V3$
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MG%5&SIFM*X9I"6QCG7L2#<P]0BA5%B.Y=)FZ#I,CO"!U.-)M?X*UWL'(3DO
MYE$6#X9N*,$V5F'Q"8>XZ5,DZ2GXQX[\XN@B"7[_"%[@CA$7K!))"TJ"%^F6
MYZ0"W3B=" OD0T*?X%8]< M"9%B1I_Q"9ML0K]:+\T',-J6(?F<X^J,C.#=>
M?24:???@VZ/1=U^U=[L'WWS8WF%[KU-OMO? 0JLMH3W;I6HUQ%CP7*%Y7EW
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M"['J5:D1S\ :)_XV'AX?O16Z%K62-O'*5@*G4,Z;&J^#"RQ,6V:BD',ES (
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M*6RF@\9SK: 7["J#)X$EE[X($L*$<YVM$Q]O)$JS$.0AI4HR*,SW(S\J8PT
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M;'6.I)LT>$V"J!.JW;K;$!//JK+>+!MQT@R13TU<4"F4XY I7GV8>$N^P5>
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MR( <-!]H](LP.D01EHU6H(NUZ!*3NB;/_Z"H[TJG>T'1.=I/7E,5T&\"4V&
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MCOS,ML\-4AS?^%1O@:64N7= Q]"L"^Z"SV_A+"-T-EM571S&=D%ZC_LTV9&
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M29RKJ]-7ZT^RY7^6<?KJ?U!+ P04    " !=A\]6/;-JMQ '   9-0  %0
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M4$L! A0#%     @ 78?/5OU9X@&\20  R/X!  X              ( !9Q8
M &5X:&EB:70Q,#(N:'1M4$L! A0#%     @ 78?/5B_"4@#Z#   N"P  !X
M             ( !3V   &5X:&EB:70Y.3$M<')E<W-R96QE87-E:G5N+FAT
M;5!+ 0(4 Q0    ( %V'SU9F%)D8/Q@   ^=   1              "  85M
M  !K<')X+3(P,C,P-C$R+FAT;5!+ 0(4 Q0    ( %V'SU9=7+.P<0(  '\'
M   1              "  ?.%  !K<')X+3(P,C,P-C$R+GAS9%!+ 0(4 Q0
M   ( %V'SU;N<51<\@H  /QD   5              "  9.(  !K<')X+3(P
M,C,P-C$R7VQA8BYX;6Q02P$"% ,4    " !=A\]6/;-JMQ '   9-0  %0
M            @ &XDP  :W!R>"TR,#(S,#8Q,E]P<F4N>&UL4$L%!@     '
-  < R $  /N:      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
